Novel Platform for Predicting Drug Effects in Patients with Acromegaly: Translational Exposure-Response Evaluation of Growth Hormone-Inhibitory Effect of Octreotide Following Growth Hormone-Releasing Hormone Stimulation

2021 ◽  
pp. JPET-AR-2021-000769
Author(s):  
Hiroyuki Iida ◽  
Tatsuya Komagata ◽  
Hirotaka Tanaka ◽  
Ryusuke Nagasawa ◽  
Takuya Nishio ◽  
...  
Endocrine ◽  
2002 ◽  
Vol 17 (2) ◽  
pp. 91-102 ◽  
Author(s):  
Hilda Martínez-Coria ◽  
L Javier López-Rosales ◽  
Martha Carranza ◽  
Laura Berumen ◽  
Maricela Luna ◽  
...  

1995 ◽  
Vol 62 (3) ◽  
pp. 313-318 ◽  
Author(s):  
Carmela Netti ◽  
Valeria Sibilia ◽  
Francesca Pagani ◽  
Norma Lattuada ◽  
Mariella Coluzzi ◽  
...  

1988 ◽  
Vol 116 (3) ◽  
pp. R1-R2 ◽  
Author(s):  
V.K.K. Chatterjee ◽  
J.A. Ball ◽  
C. Proby ◽  
J.M. Burrin ◽  
S.R. Bloom

ABSTRACT In five healthy normal male volunteers, pretreatment with the cholinergic muscarinic antagonist pirenzepine (30 mg i.v.) almost abolished the growth hormone (GH) response to a maximal dose (120 μg i.v.) of growth hormone-releasing hormone (GHRH) (GH response at 40 min 5.6 ± 1.3 mU/l with GHRH and pirenzepine vs 40.8 ± 5.3 mU/l with GHRH alone, P <0.02). Concomitant i.v. infusion of galanin (40 pmol/kg/min) with pirenzepine not only restored but significantly potentiated the GH response to GHRH (GH at 40 min 72.2 ± 10.5 mU/l, P <0.001 vs GHRH and pirenzepine, P <0.02 vs GHRH alone). Previous studies have proposed that cholinergic pathways control GH release via samatostatin and this study suggests that galanin may act by modulating hypothalamic somatostatinergic tone either directly or, possibly, by facilitating cholinergic neurotransmission.


1990 ◽  
Vol 10 (10) ◽  
pp. 1073-1080
Author(s):  
Santiago Muzzo ◽  
Raquel Burrows ◽  
Jorge Winterer ◽  
Isabel Young ◽  
Saul Malozowski ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document